Nancy Denyes sold $3,398 of ATYR
General Counsel at aTYR PHARMA INC. 899 shares at an average of $3.78, traded Feb 4, 2025, filed Feb 4, 2025.
Score components
- +15RoleOfficer
- 0Trade size$3k at market
- 0Share of holdings soldSold 3.3% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-013878, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 3, 2025 | MOption exercise Common Stock | +2,687 | - | - | 27,454 | Feb 4, 2025 |
| Feb 4, 2025 | SOpen-market sale Common Stock | -899 | $3.78 | $3,398 | 26,555 | Feb 4, 2025 |
| Feb 3, 2025 | MOption exercise Restricted Stock Unitderivative | -2,687 | $0.00 | $0 | 2,687 | Feb 4, 2025 |
Related signals
Other insiders at aTYR PHARMA INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | aTYR PHARMA INC | Jill Marie Broadfoot Chief Financial Officer | $1,521 1,558 shares | -4% | |
| 15Weak | aTYR PHARMA INC | Nancy Denyes General Counsel | $1,091 1,118 shares | -3% | |
| 25Weak | aTYR PHARMA INC | Sanjay Shukla President and CEO | $3,655 3,745 shares | -2% | |
| 57Moderate | ATYRbuy aTYR PHARMA INC | Paul Schimmel director | $912k 1,000,000 shares | +242% | |
| 25Weak | ATYRbuy aTYR PHARMA INC | Jane A Gross director | $15k 3,750 shares | +63% | |
| 15Weak | aTYR PHARMA INC | Jill Marie Broadfoot Chief Financial Officer | $4,740 1,254 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.